CORVUS PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

07 авг 2024 08:45:01 Источник NetDania Notify

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

06 авг 2024 15:01:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

02 авг 2024 08:45:18 Источник NetDania Notify

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

01 авг 2024 07:30:00 Источник Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

31 июл 2024 07:30:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

30 июл 2024 08:55:53 Источник NetDania Notify

NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

29 июл 2024 11:38:28 Источник NetDania Notify

NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

26 июл 2024 10:47:58 Источник NetDania Notify

Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases

25 июл 2024 07:30:00 Источник Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

30 май 2024 15:02:00 Источник Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

06 май 2024 15:01:00 Источник Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

02 май 2024 15:02:00 Источник Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

02 май 2024 07:30:00 Источник Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

09 апр 2024 15:01:00 Источник Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

19 мар 2024 15:02:00 Источник Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

13 мар 2024 15:02:00 Источник Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

12 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

08 фев 2024 15:05:00 Источник Nasdaq GlobeNewswire

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

06 фев 2024 15:05:00 Источник Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

23 янв 2024 16:00:00 Источник Nasdaq GlobeNewswire